Overview

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Phase:
Phase 3
Details
Lead Sponsor:
The Netherlands Cancer Institute
Treatments:
Cisplatin